🎯
LATEST VERIFIED ALGORITHMIC EXECUTION
Quantitative engine captured a net profit of +19.26% on $OC in just 23h 32m.
TAR
$TARS
🔒 US EquitiesTarsus Pharmaceuticals Inc
AVG HISTORICAL GAP
+3.26%
MAX GAP RECORD
+14.36%
🔒 PRO INSTITUTIONAL
AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡
SENTINEL HISTORICAL GAP VIEWER
// $TARS
📊 1-YEAR TIMELINE (GAPS PLOTTED)
🔮 SIMULATE SETUP 🔒
GAP INSPECTION // PLAYBACK PROTOCOL
$TARS
HISTORICAL GAP OCCURRENCE
Analyzing price jump between T-1 close and opening auction.
EVENT DATE—
GAP MAGNITUDE—
T-1 CLOSE—
OPEN PRICE—
AI DIRECTIONPRO ONLY 🔒
Bullish Opening Gap
Bearish Opening Gap
T-1 Close Baseline
CATALYSTS & GAP HISTORY
| Nov 04, 2026 Earnings Release 2026-11-04 (BEFORE OPEN (07:00)) | 🔮 UPCOMING 🔒 |
| Aug 06, 2026 Earnings Release 2026-08-06 (AFTER CLOSE) |
+0.00%
|
| May 06, 2026 Earnings Release 2026-05-06 (AFTER CLOSE) |
-3.18%
|
| Feb 23, 2026 Earnings Release 2026-02-23 (AFTER CLOSE) |
+7.13%
|
| Nov 04, 2025 Earnings Release 2025-11-04 (AFTER CLOSE) |
-4.20%
|
| Aug 06, 2025 Earnings Release 2025-08-06 (AFTER CLOSE) |
+8.00%
|
| Apr 30, 2025 Earnings Release 2025-04-30 (AFTER CLOSE) |
-0.33%
|
| Feb 25, 2025 Earnings Release 2025-02-25 (BEFORE OPEN) |
+4.17%
|
VOLATILITY & GAP BIAS
AVG GAP MOVE
6.0%
Bullish Gaps (8)
Bearish Gaps (5)
Neutral / Flat (1)
📖 Intelligence Summary
Tarsus Pharmaceuticals, Inc. is a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is…
NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗